AI Article Synopsis
- Reduced-antigen-content dTpa vaccines are generally recommended for one-time use, but a study evaluated a second booster (Boostrix™) in 164 adults who had their first dose 10 years prior.
- Pre-booster, a high percentage of participants exhibited seroprotection for diphtheria (89.4%) and tetanus (94.8%); after the booster, all showed protective antibody levels.
- The booster was well tolerated with no serious side effects, suggesting that replacing traditional Td boosters with dTpa (Boostrix™) may be beneficial.
Article Abstract
Reduced-antigen-content diphtheria-tetanus-acellular-pertussis (dTpa) vaccines are predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™, GlaxoSmithKline Biologicals) administration in 164 adults previously vaccinated with dTpa 10 years previously was evaluated. Before the decennial booster, 89.4% and 94.8% subjects were seroprotected (antibodies ≥0.1 IU/mL) for diphtheria and tetanus, respectively. One-month post-booster, all subjects were seroprotected/seropositive against all vaccine antigens. Robust GMC increases indicated a booster response similar to the first booster. The decennial booster was well tolerated without serious adverse events, consistent with product experience. This study supports replacing traditional Td boosters with dTpa, and use of Boostrix™ as a decennial booster. This study is registered at www.clinicaltrials.com NCT00548171.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2010.10.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serologic Immunity to Tetanus in the United States, National Health and Nutrition Examination Survey, 2015-2016.
Clin Infect Dis
February 2024
Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Article Synopsis
- Tetanus infections have become rare in the U.S. due to widespread vaccination, but adult vaccination rates are low, prompting a study to assess sero-immunity in those aged 6 and older.
- Analysis of data from the 2015-2016 NHANES showed that 93.8% of participants had protective antibody levels against tetanus, with high immunity rates across different demographics, although older adults had lower immunity.
- The findings highlight the effectiveness of the vaccination program, indicating the need for continued efforts to boost adult vaccination and to maintain awareness about tetanus protection.
Immune response to pertussis vaccine in COPD patients.
Sci Rep
July 2023
INSERM U955, Equipe 16, IMRB (Institut Mondor de Recherche Biomédicale), Université Paris-Est-Créteil (UPEC), 94010, Créteil, France.
Article Synopsis
- * It compares the immune responses to the pertussis vaccine between 13 COPD patients and 8 healthy volunteers, finding no significant differences in their immune responses post-vaccination.
- * The findings suggest that COPD patients respond well to pertussis vaccination, challenging the idea that they have a diminished immune response to all vaccines, underscoring the need for regular Tdap booster vaccinations in this group.
[Should Tetanus Vaccine Booster be Given Earlier in Individuals Living with HIV?].
Mikrobiyol Bul
January 2022
Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey.
The incidence rate of tetanus has dramatically decreased following the discovery of the tetanus vaccine. A decennial booster dose is necessary to maintain the protective antibody levels after the primary vaccination schedule. The recommendations for the tetanus booster doses in adult "people living with acquired immune deficiency virus (HIV)" (PLWH) is similar to those for the general population.
View Article and Find Full Text PDFA systematic review of the burden of pertussis in South Korea.
Hum Vaccin Immunother
June 2021
Medical Affairs, GSK, Singapore.
This review summarizes the published data on epidemiology and burden of pertussis in South Korea as these may be under-categorized. A systematic literature review of PubMed, SCOPUS, EMBASE and KMBASE was performed to identify published literature in South Korea since 2000. Pertussis detection rates among 19 eligible studies range from 0.
View Article and Find Full Text PDFSince 2005, a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine has been recommended by the Advisory Committee on Immunization Practices (ACIP) for adolescents and adults (1,2). After receipt of Tdap, booster doses of tetanus and diphtheria toxoids (Td) vaccine are recommended every 10 years or when indicated for wound management. During the October 2019 meeting of ACIP, the organization updated its recommendations to allow use of either Td or Tdap where previously only Td was recommended.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!